Skip to main content
Log in

Hormontherapie mit Östrogenen und Gestagenen in der Peri- und Postmenopause

Hormone therapy with estrogens and gestagens in peri- and post-menopause

  • Schwerpunkt: Hormontherapie
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Die Therapie mit Östrogenen (bei nicht hysterektomierten Frauen in Kombination mit Gestagenen) ist die wirksamste Behandlung von klimakterischen Beschwerden. Bis vor einigen Jahren wurde diese Hormontherapie auch als ideale Prävention von Herz-Kreislauf-Erkrankungen, Osteoporose, Demenz und anderen Erkrankungen angesehen. Die Ergebnisse von neuen Studien haben jedoch zu einem Umdenken geführt. Eine Hormontherapie sollte nur bei eindeutigen Indikationen (unerträgliche klimakterische Beschwerden sowie mit Einschränkung Osteoporoseprävention/-therapie) in möglichst geringer Dosierung und möglichst kurzer Dauer durchgeführt werden.

Abstract

Hormone therapy with estrogens (combined with progestin for women who have not been hysterectomized) is the most efficacious treatment for climacteric symptoms. A few years ago hormone therapy was considered to be an ideal prevention for cardio-vascular disease, osteoporosis, dementia and other diseases. Large prospective randomized trials have changed this paradigm. Hormone therapy should only be used with a clear indication (moderate to severe climacteric symptoms and – with limitations – prevention of osteoporosis). The lowest effective dose should be used for the shortest possible time.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Barrett-Connor E (2007) Hormones and heart disease in women: the timing hypothesis. Am J Epidemiol 166: 506–510

    Article  PubMed  Google Scholar 

  2. Bundesinstitut für Arzneimittel und Medizinprodukte http://www.bfarm.de/Presse/mitteil_2004/index.php?pv=&more=0410.php

  3. Chen WY, Manson JE, Hankinson SE et al. (2006) Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166: 1027–1032

    Article  PubMed  CAS  Google Scholar 

  4. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe im Konsens mit dem Berufsverband der Frauenärzte (2006) Konsensusempfehlungen zur Hormontherapie (HT) im Klimakterium und der Postmenopause. http://www.dggg.de

  5. Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23: 357–367

    Article  PubMed  Google Scholar 

  6. Emons G, Huschmand-Nia A, Krauss T, Hinney B (2004) Hormone replacement therapy and endometrial cancer. Onkologie 27: 207–210

    Article  PubMed  CAS  Google Scholar 

  7. Emons G (2006) Hormonsubstitution bei Frauen in der Postmenopause. Kassenarzt 5: 36–40

    Google Scholar 

  8. Emons G (2006) Sind Östrogene Karzinogene? Frauenarzt 47: 430–435

    Google Scholar 

  9. Farquhar CM, Marjoribanks J, Lethaby A et al. the Cochrane HT Study Group (2005) Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 3: CD004143

    PubMed  Google Scholar 

  10. Gemeinsames Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen (2007) Brustkrebsinzidenz bei 45–59-jährigen Frauen rückläufig. http://www.berlin.de/gkr

  11. Glass AG, Lacey JV, Carreon JD, Hoover RN (2007) Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 99: 1152–1161

    Article  PubMed  Google Scholar 

  12. Grady D, Rubin SM, Petiti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117: 1016–1037

    PubMed  CAS  Google Scholar 

  13. Grady D (2006) Management of menopausal symptoms. N Engl J Med 355: 2338–2347

    Article  PubMed  CAS  Google Scholar 

  14. Hulley S, Grady D, Bush T et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613

    Article  PubMed  CAS  Google Scholar 

  15. Jemal A, Ward E, Thun MJ ( 2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9: R28

    Article  PubMed  Google Scholar 

  16. Katalinic A, Rawal R (2008) Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107: 427–430

    Article  PubMed  CAS  Google Scholar 

  17. Maki PM, Gast MJ, Vieweg AJ et al. (2007) Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 69: 1322–1330

    Article  PubMed  CAS  Google Scholar 

  18. Manson JE, Allison MA, Rossouw JE et al. (2007) Estrogen therapy and coronary-artery calcification. N Eng J Med 356: 2591–2602

    Article  CAS  Google Scholar 

  19. Million Women Study Collaborators (2005) Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 365: 1543–1551

    Article  Google Scholar 

  20. Million Women Study Collaborators (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369: 1703–1710

    Article  Google Scholar 

  21. Nedrow A, Miller J, Walker M et al. (2006) Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 166: 1453–1465

    Article  PubMed  Google Scholar 

  22. North American Menopause Society (2007) Estrogen and progesteron use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 14: 168–182

    Article  Google Scholar 

  23. Pines A, Sturdee DW, Birkhäuser MH et al. (2007) IMS updated recommendations on postmenopausal hormone therapy. Climacteric 10: 181–194

    Article  PubMed  CAS  Google Scholar 

  24. Ravdin PM, Cronin KA, Howlader N et al. (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356: 1670–1674

    Article  PubMed  CAS  Google Scholar 

  25. Robbins AS, Clarke CA (2007) Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25: 3437–3439

    Article  PubMed  Google Scholar 

  26. Rossouw JE, Prentice RL, Manson JE et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465–1477

    Article  PubMed  CAS  Google Scholar 

  27. Shah NR, Borenstein J, Dubois RW (2005) Postmenopausal hormone therapy and breast cancer: a systematic review and metaanalysis. Menopause 12: 668–678

    Article  PubMed  Google Scholar 

  28. Stefanick ML, Anderson GL, Margolis KL et al. (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295: 1647–1657

    Article  PubMed  CAS  Google Scholar 

  29. Wiegratz I, Kuhl H (2007) Praxis der Hormontherapie in der Peri- und Postmenopause. Gynakol Endokrinol 5: 141–149

    Article  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G. Emons.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Emons, G. Hormontherapie mit Östrogenen und Gestagenen in der Peri- und Postmenopause. Internist 49, 553–558 (2008). https://doi.org/10.1007/s00108-008-2107-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-008-2107-y

Schlüsselwörter

Keywords

Navigation